Puzzle Medical Devices Inc. Receives U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Its Revolutionary Minimally Invasive Transcatheter Heart Pump
- U.S. stocks close down on news of Biden tax proposal
- Biden To Propose Capital Gains Tax As High As 43.4% For Wealthy - Bloomberg
- Intel (INTC) Tops Q1 EPS by 24c, Offers Guidance
- Snap (SNAP) Tops Q1 EPS by 5c, DAUs were 280 million, Offers Guidance
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
MONTREAL, Feb. 8, 2021 /PRNewswire/ - Puzzle Medical Devices Inc., (www.puzzlemed.com) announced today that the U.S. Food and Drug Administration (FDA) has granted the company a Breakthrough Device Designation for its revolutionary transcatheter pump to address heart failure.
The FDA Breakthrough Device Program is intended to help patients receive more timely access to certain medical devices that have the potential to provide more effective treatment for life-threatening or irreversibly debilitating diseases or conditions, including a prioritized review of market approval regulatory submissions.
"The FDA's recognition of Puzzle Medical's heart pump as a Breakthrough Device is a testimony to the innovative and disruptive nature of this device," said Philippe Généreux, MD, interventional cardiologist at Gagnon Cardiovascular Institute, Morristown Medical Center, New Jersey, USA, and Chief Medical Officer of Puzzle Medical. "This novel technology has the potential to help millions of patients suffering from heart failure who currently have no treatment option other than medical therapy."
Puzzle Medical's focus is to improve patient quality of life and reduce the global economic burden related to heart failure. Puzzle Medical is developing a proprietary transcatheter heart pump associated with minimal trauma to the blood components, allowing for safe and efficient heart support without open-heart surgery.
"I have been impressed by the progress made by the Puzzle Medical team so far. Their device clearly answers an unmet need among patients suffering from heart failure," said Professor Alain Cribier, MD, of Rouen, France.
"Puzzle Medical is excited about this important milestone and is thankful to the FDA for the Breakthrough Device Designation," said Jade Doucet-Martineau, co-founder and CEO of Puzzle Medical. "Leveraging decades of expertise in the development of transcatheter therapies, the Puzzle Medical team will fiercely continue the development of the most efficient and safest heart pump ever created."
About Puzzle Medical Devices Inc.
Puzzle Medical Devices Inc. (www.puzzlemed.com) is a Canadian company specializing in the development of a minimally invasive transcatheter heart pump. Puzzle Medical enables mechanical hemodynamic support to be more efficacious, safer, and more economical, resulting in increased accessibility, improved patient quality of life and reduction of the global economic burden related to the disease. To date, Puzzle Medical has successfully completed acute in-vivo preclinical implantations with tremendous success.
View original content:http://www.prnewswire.com/news-releases/puzzle-medical-devices-inc-receives-us-food-and-drug-administration-fda-breakthrough-device-designation-for-its-revolutionary-minimally-invasive-transcatheter-heart-pump-301221606.html
SOURCE Puzzle Medical Devices Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LMU Loyola Law School Professor Justin Levitt Named White House Senior Policy Advisor
- On Earth Day, Z Sphere Development LLC and WeSolar CSP Inc. Announce MOU Collaboration to Safeguard Island Communities From Natural Disasters
- Nevada's Safety Consultation and Training Section Awards Desert Star Energy Center With Top Safety Honor